NCT05105139View on ClinicalTrials.gov

Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp

CompletedOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

February 15, 2022

Study Completion Date

February 25, 2022

Conditions
Seborrheic DermatitisPsoriasis of Scalp
Interventions
OTHER

Allantoin/ Coal Tar/ Clioquinol

Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use

OTHER

Allantoin/ Coal Tar/ Clioquinol/ Triclosan

Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us

Trial Locations (1)

11000

Laboratorio Silanes, S.A. de C.V., Mexico City

All Listed Sponsors
lead

Laboratorios Silanes S.A. de C.V.

INDUSTRY

NCT05105139 - Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp | Biotech Hunter | Biotech Hunter